Clinical trial
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell…
NCT00312845 · Millennium Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00312845 |
|---|---|
| Title | Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma |
| Official title | A Randomized, Open-Label, Multicenter Study of VELCADE With Rituximab or Rituximab Alone in Subjects With Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-cell Non-Hodgkin's Lymphoma |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Collaborators | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Bortezomib + Rituximab, Rituximab |
| Enrollment | 676 |
| Start date | Mar 1, 2006 |
| Primary completion | Jun 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Apr 11, 2006 |
| Last update posted | Jun 25, 2012 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, China, Cyprus, Czechia, Finland, France, Germany, Greece and 20 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: